Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H20N2O4S2 |
| Molecular Weight | 392.492 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
InChI
InChIKey=TTYKUKSFWHEBLI-DLBZAZTESA-N
InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
| Molecular Formula | C18H20N2O4S2 |
| Molecular Weight | 392.492 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PF-04958242 is an AMPA receptor potentiator for the potential treatment of cognitive deficits in schizophrenia. But recent study revealed that there were no pharmacokinetic interactions between PF-04958242 and ketamine. 'High-impact' AMPAR potentiators like PF-04958242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia. In addition, a clinical study was underway to evaluate the effects of PF-049582432 in subjects with age-related hearing loss in the US. PF-04958242 has been classified as glycine transporter (GLYT-1) inhibitor in this study. However, this development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A Randomized Clinical Trial. | 2015 Jul |
|
| The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242). | 2015 May 28 |
|
| Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. | 2017 Nov |
|
| Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery. | 2018 Feb |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:28:07 GMT 2023
by
admin
on
Sat Dec 16 01:28:07 GMT 2023
|
| Record UNII |
9G1A824CC2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11843
Created by
admin on Sat Dec 16 01:28:07 GMT 2023 , Edited by admin on Sat Dec 16 01:28:07 GMT 2023
|
PRIMARY | |||
|
300000000980
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
9G1A824CC2
Created by
admin on Sat Dec 16 01:28:07 GMT 2023 , Edited by admin on Sat Dec 16 01:28:07 GMT 2023
|
PRIMARY | |||
|
BIIB-104
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
11917
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
49853967
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
C186393
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
JK-01
Created by
admin on Sat Dec 16 01:28:08 GMT 2023 , Edited by admin on Sat Dec 16 01:28:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707379
Created by
admin on Sat Dec 16 01:28:07 GMT 2023 , Edited by admin on Sat Dec 16 01:28:07 GMT 2023
|
PRIMARY | |||
|
DTXSID001337272
Created by
admin on Sat Dec 16 01:28:07 GMT 2023 , Edited by admin on Sat Dec 16 01:28:07 GMT 2023
|
PRIMARY | |||
|
1258963-59-5
Created by
admin on Sat Dec 16 01:28:07 GMT 2023 , Edited by admin on Sat Dec 16 01:28:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
|
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM) |
|
||
|
TARGET -> ACTIVATOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
